Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review

Date: February 28, 2018
Pages: 65
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A0EFA65379DEN
Leaflet:

Download PDF Leaflet

Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review
Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc Key Recent Developments

Feb 01,2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results
Jan 23,2018: Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model
Jan 09,2018: BC Platforms to Provide Big Data Driven Research Solutions to Amgen in Cardiovascular Diseases and Oncology
Dec 12,2017: Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
Dec 11,2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

Amgen Inc - Key Facts
Amgen Inc - Key Employees
Amgen Inc - Key Employee Biographies
Amgen Inc - Major Products and Services
Amgen Inc - History
Amgen Inc - Company Statement
Amgen Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Amgen Inc - Business Description
Business Segment: Human Therapeutics
Overview
Performance
Key Stats
Business Segment: Other Revenues
Performance
Business Segment: Other Segment
Overview
Geographical Segment: Rest of the world (ROW)
Performance
Geographical Segment: United States
Performance
R&D Overview
Amgen Inc - Corporate Strategy
Amgen Inc - SWOT Analysis
SWOT Analysis - Overview
Amgen Inc - Strengths
Amgen Inc - Weaknesses
Amgen Inc - Opportunities
Amgen Inc - Threats
Amgen Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Amgen Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 01, 2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results
Jan 23, 2018: Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model
Jan 09, 2018: BC Platforms to Provide Big Data Driven Research Solutions to Amgen in Cardiovascular Diseases and Oncology
Dec 12, 2017: Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires
Dec 07, 2017: New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results
Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors
Oct 06, 2017: Amgen And LabCentral Open Nomination Process For Lab Residency
Sep 25, 2017: Amgen Provides Update On Hurricane Maria

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Amgen Inc, Key Facts
Amgen Inc, Key Employees
Amgen Inc, Key Employee Biographies
Amgen Inc, Major Products and Services
Amgen Inc, History
Amgen Inc, Other Locations
Amgen Inc, Subsidiaries
Amgen Inc, Joint Venture
Amgen Inc, Key Competitors
Amgen Inc, Annual Ratios
Amgen Inc, Annual Ratios (Cont.1)
Amgen Inc, Annual Ratios (Cont.2)
Amgen Inc, Interim Ratios
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Amgen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Amgen Inc, Performance Chart (2013 - 2017)
Amgen Inc, Ratio Charts
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Teva Pharmaceutical Industries Ltd
SynZyme Technologies LLC
Sangamo Therapeutics Inc
Roxane Laboratories Inc
Quanta BioDesign Ltd
Pfenex Inc
Novartis AG
Nordion (Canada) Inc
NewLink Genetics Corp
Millennium Pharmaceuticals Inc
Ligand Pharmaceuticals Inc
Innovation Pharmaceuticals Inc
GlaxoSmithKline Plc
Genentech Inc
Fresenius Medical Care AG & Co KGaA
F. Hoffmann-La Roche Ltd
Exelixis Inc
Eli Lilly and Co
Celgene Corp
Bristol-Myers Squibb Co
AbbVie Inc
Skip to top


Ask Your Question

Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: